Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (491-500 of 497) with videos related to

Pageof 50
Sort By:
You have reached the last page of results.This site can display upto 497 results.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trialStuart J Connolly, John W Eikelboom, Jackie Bosch, et al.
Blood Advances|December 22, 2020
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)Philip Connor, Mayte Sánchez van Kammen, Anthonie W A Lensing, et al.
Stroke|September 21, 2020
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI SubstudyMukul Sharma, Robert G Hart, Eric E Smith, et al.
The Lancet. Haematology|November 9, 2019
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialChristoph Male, Anthonie W A Lensing, Joseph S Palumbo, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 12, 2018
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized TrialScott E Kasner, Pablo Lavados, Mukul Sharma, et al.
European Stroke Journal|April 23, 2019
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trialRobert G Hart, Mukul Sharma, Hardi Mundl, et al.
The New England Journal of Medicine|May 17, 2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined SourceRobert G Hart, Mukul Sharma, Hardi Mundl, et al.
Pageof 50

Showing results (491-500 of 497) with videos related to

Sort By:
Pageof 50
You have reached the last page of results.This site can display upto 497 results.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trialStuart J Connolly, John W Eikelboom, Jackie Bosch, et al.
Blood Advances|December 22, 2020
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)Philip Connor, Mayte Sánchez van Kammen, Anthonie W A Lensing, et al.
Stroke|September 21, 2020
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI SubstudyMukul Sharma, Robert G Hart, Eric E Smith, et al.
The Lancet. Haematology|November 9, 2019
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialChristoph Male, Anthonie W A Lensing, Joseph S Palumbo, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 12, 2018
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized TrialScott E Kasner, Pablo Lavados, Mukul Sharma, et al.
European Stroke Journal|April 23, 2019
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trialRobert G Hart, Mukul Sharma, Hardi Mundl, et al.
The New England Journal of Medicine|May 17, 2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined SourceRobert G Hart, Mukul Sharma, Hardi Mundl, et al.
Pageof 50